HUE036035T2 - Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra - Google Patents

Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra

Info

Publication number
HUE036035T2
HUE036035T2 HUE14812465A HUE14812465A HUE036035T2 HU E036035 T2 HUE036035 T2 HU E036035T2 HU E14812465 A HUE14812465 A HU E14812465A HU E14812465 A HUE14812465 A HU E14812465A HU E036035 T2 HUE036035 T2 HU E036035T2
Authority
HU
Hungary
Prior art keywords
kromon
dopamine
derivative
treatment
receptor antagonist
Prior art date
Application number
HUE14812465A
Other languages
English (en)
Hungarian (hu)
Inventor
Agnes Auclair
Paul Moser
Pierre Sokoloff
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of HUE036035T2 publication Critical patent/HUE036035T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE14812465A 2013-12-13 2014-12-12 Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra HUE036035T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306726 2013-12-13

Publications (1)

Publication Number Publication Date
HUE036035T2 true HUE036035T2 (hu) 2018-06-28

Family

ID=49883003

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14812465A HUE036035T2 (hu) 2013-12-13 2014-12-12 Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra

Country Status (29)

Country Link
US (1) US10028948B2 (enExample)
EP (1) EP3079688B1 (enExample)
JP (1) JP6419826B2 (enExample)
KR (1) KR102280530B1 (enExample)
CN (1) CN105792824B (enExample)
AU (1) AU2014363428B2 (enExample)
BR (1) BR112016012552A8 (enExample)
CA (1) CA2932791C (enExample)
CY (1) CY1119907T1 (enExample)
DK (1) DK3079688T3 (enExample)
ES (1) ES2657706T3 (enExample)
HR (1) HRP20180323T8 (enExample)
HU (1) HUE036035T2 (enExample)
IL (1) IL245996B (enExample)
LT (1) LT3079688T (enExample)
MA (1) MA39076A1 (enExample)
MX (1) MX372922B (enExample)
MY (1) MY172937A (enExample)
NO (1) NO3079688T3 (enExample)
NZ (1) NZ720868A (enExample)
PL (1) PL3079688T3 (enExample)
PT (1) PT3079688T (enExample)
RS (1) RS56931B1 (enExample)
RU (2) RU2019104946A (enExample)
SA (1) SA516371298B1 (enExample)
SI (1) SI3079688T1 (enExample)
TN (1) TN2016000213A1 (enExample)
UA (1) UA117271C2 (enExample)
WO (1) WO2015086836A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20146052B (en) 2008-07-16 2014-03-10 Richter Gedeon Vegyeszeti Gyar Rt Pharmaceutical formulations containing dopamine receptor ligands
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
CN114787380A (zh) * 2019-09-11 2022-07-22 牛津生物动力公共有限公司 诊断用染色体标志物
KR20220021157A (ko) 2020-08-13 2022-02-22 원광대학교산학협력단 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682953B1 (fr) 1991-10-23 1995-04-21 Inst Nat Sante Rech Med Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique.
DE4229880A1 (de) * 1992-09-04 1994-03-31 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
IL142388A0 (en) * 1998-10-08 2002-03-10 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
ES2367868T3 (es) * 2004-09-20 2011-11-10 Mount Sinai School Of Medicine Uso de memantina (namenda) para tratar el autismo, la compulsividad y la impulsividad.
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
FR2949465B1 (fr) * 2009-09-01 2011-08-12 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012157463A1 (en) * 2011-05-13 2012-11-22 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device
FR2976179A1 (fr) * 2011-06-09 2012-12-14 Pf Medicament Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Also Published As

Publication number Publication date
PL3079688T3 (pl) 2018-05-30
ES2657706T3 (es) 2018-03-06
MX2016007612A (es) 2016-09-09
HRP20180323T8 (hr) 2019-01-25
JP2016540000A (ja) 2016-12-22
NO3079688T3 (enExample) 2018-04-21
CN105792824A (zh) 2016-07-20
RU2019104946A (ru) 2019-04-01
MA39076A1 (fr) 2017-05-31
AU2014363428A1 (en) 2016-06-23
CN105792824B (zh) 2018-08-03
US20160303117A1 (en) 2016-10-20
DK3079688T3 (da) 2018-01-29
WO2015086836A1 (en) 2015-06-18
MX372922B (es) 2020-04-27
AU2014363428B2 (en) 2019-09-12
IL245996B (en) 2018-11-29
CA2932791C (en) 2021-11-09
RS56931B1 (sr) 2018-05-31
SA516371298B1 (ar) 2018-06-07
HK1223563A1 (zh) 2017-08-04
UA117271C2 (uk) 2018-07-10
US10028948B2 (en) 2018-07-24
RU2686110C1 (ru) 2019-04-24
MY172937A (en) 2019-12-16
LT3079688T (lt) 2018-02-12
HRP20180323T1 (hr) 2018-04-06
KR20160088886A (ko) 2016-07-26
KR102280530B1 (ko) 2021-07-21
CA2932791A1 (en) 2015-06-18
EP3079688B1 (en) 2017-11-22
CY1119907T1 (el) 2018-06-27
NZ720868A (en) 2022-04-29
SI3079688T1 (en) 2018-03-30
IL245996A0 (en) 2016-07-31
JP6419826B2 (ja) 2018-11-07
EP3079688A1 (en) 2016-10-19
TN2016000213A1 (en) 2017-10-06
BR112016012552A8 (pt) 2022-11-08
PT3079688T (pt) 2018-02-28

Similar Documents

Publication Publication Date Title
CY2023027I2 (el) Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων
IL283032A (en) Preparations for oral administration of tofacitinib
IL246025B (en) Formulations for neoplasia vaccines
PL2919766T3 (pl) Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
DK2794626T6 (da) E-selectin-antagonistforbindelser
ITMI20131499A1 (it) Filtro per orinatoio
HUE049345T2 (hu) Nyújtott hatóanyag-leadású dózisformák JAK1 inhibitorhoz
DK3024468T3 (da) T-cellereceptorer
HRP20181393T1 (hr) Oralno doziranje spojeva glp-1
DK2890434T3 (da) Lægemiddeladministrationsanordning
DK2970389T3 (da) Farmaceutiske forbindelser
UA30221S (uk) Внутрішньоротовий пристрій
EP2835693A4 (en) Image forming device
EP2750373A4 (en) Imaging device
HUE036035T2 (hu) Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra
HRP20182115T1 (hr) UPORABA MOLEKULE miR172 ZA SMANJENJE UPALE
UA30220S (uk) Внутрішньоротовий пристрій
ZA201601645B (en) Bendamustine pharmaceutical compositions
BR112016001395A2 (pt) forma de dosagem unitária oral sólida de metaxalona
ES1074561Y (es) Aparato intraoral anti-ronquido
TH1601003463A (th) อนุพันธ์โครโมนในฐานะแอนตะกอนิสต์ของโดพามีน d3 รีเซปเตอร์ สำหรับการใช้เพื่อการรักษากลุ่มโรคออทิสติก
UA30721S (uk) Міні-бункер для сіялки
DK2890435T3 (da) Lægemiddeladministrationsanordning
UA24793S (uk) Насос - дозатор для косметичних засобів
FI20115180L (fi) Koostumus käytettäväksi sairauden hoidossa